NEW YORK, November 8, 2016 /PRNewswire/ --
In today's pre-market research, Stock-Callers.com presents four Biotechequities for review: Illumina Inc. (NASDAQ: ILMN), Peregrine Pharmaceuticals Inc. (NASDAQ: PPHM), Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX), and Vanda Pharmaceuticals Inc. (NASDAQ: VNDA). These companies belong to the Healthcare sector which is the
On Monday, shares in San Diego, California headquartered Illumina Inc. recorded a trading volume of 1.43 million shares, which was above their three months average volume of 1.30 million shares. The stock ended the session 1.82% higher at $137.08. The Company's are trading 11.01% below their 200-day moving average. Moreover, shares of Illumina, which provides sequencing and array-based solutions for genetic analysis, have a Relative Strength Index (RSI) of 37.15.
On November 02nd, 2016, research firm First Analysis Sec downgraded the Company's stock rating from 'Equal-Weight' to 'Underweight'. The research firm also revised downwards its previous target price from $130 to $116.
On November 07th, 2016, Illumina announced the launch of TruSight® Tumor 170, a 170 gene next-generation sequencing solution to support the transformation of the tumor-profiling paradigm from a series of single-gene tests to a multi-analyte approach, providing a more thorough picture of a tumor's genomic landscape. TruSight Tumor 170 offers an integrated DNA and RNA enrichment-based workflow, targeting cancer-related genetic aberrations, including small variants, gene amplifications, gene fusions, and splice variants. Designed to support limited nucleic acid input from formalin-fixed, paraffin-embedded samples, TruSight Tumor 170 facilitates efficient evaluation of biomarkers. Your complete research report on ILMN can be retrieved for free at: http://stock-callers.com/registration/?symbol=ILMN
Tustin, California headquartered Peregrine Pharmaceuticals Inc.'s stock closed the day 3.46% higher at $0.30 and with a total trading volume of 451,209 shares. Shares of the Company, which researches and develops monoclonal antibodies for the treatment of cancer in the US, are trading 19.19% below their 50-day moving average. The stock has an RSI of 34.12.
On October 24th, 2016, Peregrine Pharma announced the presentation of preclinical study data demonstrating that phosphatidylserine (PS)-targeting antibodies similar to bavituximab are able to enhance the anti-tumor activity of anti-PD-L1 therapy in a model of triple negative breast cancer (TNBC). Data showed that a combination of anti-PS and anti-PD-L1 therapies, with or without paclitaxel, led to greater anti-tumor responses than any of the treatments administered as single agents or dual treatment combinations with paclitaxel, in the well-characterized E0771 murine model of TNBC. PPHM free report is just a click away at: http://stock-callers.com/registration/?symbol=PPHM
Shares in The Woodlands, Texas headquartered Lexicon Pharmaceuticals Inc. recorded a trading volume of 602,686 shares. The stock ended yesterday's trading session 3.13% higher at $14.83. The Company's shares have advanced 11.42% on an YTD basis. The stock is trading above its 200-day moving average by 6.12%. Furthermore, shares of Lexicon Pharma, which focuses on the discovery and development of pharmaceutical products for the treatment of human diseases, have an RSI of 37.90.
On November 07th, 2016, Lexicon Pharma announced that it has obtained exclusive research, development, and commercialization rights to LX9211 (BMS-986176), a development candidate for neuropathic pain that was jointly developed by Lexicon and Bristol-Myers Squibb Co. as part of their neuroscience drug discovery alliance. Additional small molecule compounds acting through the same target as LX9211 are also included in the exclusive arrangement. LX9211 is currently completing IND-enabling studies, with Phase 1 clinical trials anticipated to commence during 2017. LX9211 is an orally-administered small molecule for the treatment of neuropathic pain. In preclinical studies, LX9211 has shown robust efficacy in models of neuropathic pain and is well-tolerated at and above efficacious doses in animals. Sign up for your complimentary research report on LXRX at: http://stock-callers.com/registration/?symbol=LXRX
Washington, the District of Columbia headquartered Vanda Pharmaceuticals Inc.'s stock finished Monday's session 2.11% higher at $14.55 with a total trading volume of 698,879 shares. The Company's shares have advanced 17.06% over the previous three months and 56.28% since the start of this year. The stock is trading above its 200-day moving average by 29.04%. Additionally, shares of Vanda Pharma, which focuses on the development and commercialization of products for the treatment of central nervous system disorders, have an RSI of 40.04.
On November 02nd, 2016, Vanda Pharma reported that total revenues grew to $38.5 million, a 7% increase compared to Q2 2016 and a 36% increase compared to Q3 2015. For the reported quarter, the company's non-GAAP net income was $4.6 million compared to a non-GAAP net loss of $4.5 million for Q3 2015. Register for free on Stock-Callers.com and download the latest research report on VNDA at: http://stock-callers.com/registration/?symbol=VNDA
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: email@example.com Phone number: +44 330 808 3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
Subscribe to our Free Newsletters!
Acute coronary syndrome (ACS) is a sudden, acute life-threatening condition caused by a dramatic ...
Sclerotherapy is a procedure used to treat spider veins, varicose veins and hemorrhoids by directly ...
HELLP syndrome is a rare but serious complication that affects pregnant women. If detected on time, ...View All